Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daraxonrasib in resected pancreatic ductal adenocarcinoma
NCT07252232Phase 3Recruiting
- Sponsor
- Revolution Medicines
- Start
- Dec 2025
- Primary completion
- May 2029
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 10
01
Overview
A Phase 3 trial of daraxonrasib in pancreatic ductal adenocarcinoma (PDAC), sponsored by Revolution Medicines. Started Dec 2025; status: recruiting.
02
Drugs
daraxonrasib
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07252232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252232.